Mori, Masaaki
Hara, Takuma
Kikuchi, Masako
Shimizu, Hiroyuki
Miyamoto, Tomoyuki
Iwashima, Satoru http://orcid.org/0000-0003-2713-321X
Oonishi, Tatsuya
Hashimoto, Kunio
Kobayashi, Norimoto
Waki, Kenji
Suzuki, Yasuo
Otsubo, Yoshikazu
Yamada, Hiroshi
Ishikawa, Chikao
Kato, Taichi
Fuse, Shigeto
Article History
Received: 30 June 2017
Accepted: 5 December 2017
First Online: 31 January 2018
Competing Interests
: M.M. received personal fees from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and grants from Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; UCB Japan Co., Ltd.; Towa Pharmaceutical Co., Ltd.; AbbVie G.K.; Japan Blood Products Organization; Ayumi Pharmaceutical Co.; CSL Behring; and Nippon Kayaku Co., Ltd.; and personal fees from AbbVie G.K.; MSD K.K.; Daiichi Sankyo Co., Ltd.; and Taisho Pharmaceutical Co., Ltd. outside the submitted work. T.H. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. M.K. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. H.S. received grants from Mitsubishi Tanabe Pharma Corporation, during the conduct of the trial and personal fees from Taisho Toyama Pharmaceutical Co., Ltd. outside the submitted work. T.M. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. S.I. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. T.O. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation and TEIJIN PHARMA Limited outside the submitted work. K.H. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. N.K. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. K.W. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. Y.S. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. Y.O. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial. H.Y. received personal fees from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. C.I. received personal fees from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. T.K. received grants from Mitsubishi Tanabe Pharma Corporation during the conduct of the trial and personal fees from Actelion Pharmaceuticals Japan, Ltd.; Astellas Pharma Inc.; and Meiji Seika Pharma Co., Ltd. outside the submitted work. S.F. received personal fees from Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Nihon Pharmaceutical Co., Ltd.; and Japan Blood Products Organization outside the submitted work.